Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma

Carolyn D. Runowicz, Scott Wadler, Lorna Rodriguez-Rodriguez, Peter Litwin, Mark Shaves, Katherine A. O'Hanlan, Gary L. Goldberg, Catherine T. Tomainov, Richard Byrnes

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalGynecologic Oncology
Issue number3
StatePublished - Sep 1989

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma'. Together they form a unique fingerprint.

Cite this